Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I

Emily Griffiths, Helena Ong, Mark J Soloski, Martin F. Bachmann, Pamela S. Ohashi, Daniel E. Speiser

Research output: Contribution to journalArticle

Abstract

Cytotoxic T Cells (CTLs) can exhibit considerable antitumor activity. Thus far, the characterized tumor peptide antigens recognized by CTLs are all presented by classical MHC class Ia molecules [human lymphocyte antigen A (HLA-A), HLA-B, and HLA-C in humans and H-2K, H-2D, and H-2L in mice]. Here we show that CTLs recognized peptides presented by nonclassical MHC class Ib molecule Qa-1b expressed by tumor cells. These CTLs conferred in vivo protection by delaying the growth of Qa-1b-expressing B78H1 melanoma cells pulsed with Qa-1b-binding peptides Cw4L or B35L and injected s.c. in C57BL/6 mice. A hierarchy of the peptides was found with regard to their ability to trigger CTLs; Cw4L stimulated a strong CTL response. The closely related and cross-reactive peptide B35L induced a weaker CTL response but was still efficient in sensitizing the target cells. Finally, Qa-1b-expressing melanoma cells without exogenous peptides were not immunogenic but possibly expressed endogenous cross-reactive antigenic peptides. The data are compatible with earlier findings that CTL activation requires relatively strong peptide antigens, whereas subsequent effector functions are also mediated by weak peptide analogues. In conclusion, CTLs mediated tumor immunity through the recognition of peptides presented by nonclassical MHC class Ib molecules. The identification of similar CTLs in humans may facilitate the vaccination of cancer patients because MHC class Ib/peptide complexes are much less polymorphic than MHC class Ia/peptide complexes.

Original languageEnglish (US)
Pages (from-to)4682-4687
Number of pages6
JournalCancer Research
Volume58
Issue number20
StatePublished - Oct 15 1998

Fingerprint

T-Lymphocytes
Peptides
Neoplasms
Melanoma
HLA-C Antigens
HLA-B Antigens
Neoplasm Antigens
Inbred C57BL Mouse
Cellular Immunity
Vaccination
Lymphocytes
Antigens
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Griffiths, E., Ong, H., Soloski, M. J., Bachmann, M. F., Ohashi, P. S., & Speiser, D. E. (1998). Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I. Cancer Research, 58(20), 4682-4687.

Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I. / Griffiths, Emily; Ong, Helena; Soloski, Mark J; Bachmann, Martin F.; Ohashi, Pamela S.; Speiser, Daniel E.

In: Cancer Research, Vol. 58, No. 20, 15.10.1998, p. 4682-4687.

Research output: Contribution to journalArticle

Griffiths, E, Ong, H, Soloski, MJ, Bachmann, MF, Ohashi, PS & Speiser, DE 1998, 'Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I', Cancer Research, vol. 58, no. 20, pp. 4682-4687.
Griffiths E, Ong H, Soloski MJ, Bachmann MF, Ohashi PS, Speiser DE. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I. Cancer Research. 1998 Oct 15;58(20):4682-4687.
Griffiths, Emily ; Ong, Helena ; Soloski, Mark J ; Bachmann, Martin F. ; Ohashi, Pamela S. ; Speiser, Daniel E. / Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I. In: Cancer Research. 1998 ; Vol. 58, No. 20. pp. 4682-4687.
@article{ebd0f1bd1744489781e6b93566c733f4,
title = "Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I",
abstract = "Cytotoxic T Cells (CTLs) can exhibit considerable antitumor activity. Thus far, the characterized tumor peptide antigens recognized by CTLs are all presented by classical MHC class Ia molecules [human lymphocyte antigen A (HLA-A), HLA-B, and HLA-C in humans and H-2K, H-2D, and H-2L in mice]. Here we show that CTLs recognized peptides presented by nonclassical MHC class Ib molecule Qa-1b expressed by tumor cells. These CTLs conferred in vivo protection by delaying the growth of Qa-1b-expressing B78H1 melanoma cells pulsed with Qa-1b-binding peptides Cw4L or B35L and injected s.c. in C57BL/6 mice. A hierarchy of the peptides was found with regard to their ability to trigger CTLs; Cw4L stimulated a strong CTL response. The closely related and cross-reactive peptide B35L induced a weaker CTL response but was still efficient in sensitizing the target cells. Finally, Qa-1b-expressing melanoma cells without exogenous peptides were not immunogenic but possibly expressed endogenous cross-reactive antigenic peptides. The data are compatible with earlier findings that CTL activation requires relatively strong peptide antigens, whereas subsequent effector functions are also mediated by weak peptide analogues. In conclusion, CTLs mediated tumor immunity through the recognition of peptides presented by nonclassical MHC class Ib molecules. The identification of similar CTLs in humans may facilitate the vaccination of cancer patients because MHC class Ib/peptide complexes are much less polymorphic than MHC class Ia/peptide complexes.",
author = "Emily Griffiths and Helena Ong and Soloski, {Mark J} and Bachmann, {Martin F.} and Ohashi, {Pamela S.} and Speiser, {Daniel E.}",
year = "1998",
month = "10",
day = "15",
language = "English (US)",
volume = "58",
pages = "4682--4687",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I

AU - Griffiths, Emily

AU - Ong, Helena

AU - Soloski, Mark J

AU - Bachmann, Martin F.

AU - Ohashi, Pamela S.

AU - Speiser, Daniel E.

PY - 1998/10/15

Y1 - 1998/10/15

N2 - Cytotoxic T Cells (CTLs) can exhibit considerable antitumor activity. Thus far, the characterized tumor peptide antigens recognized by CTLs are all presented by classical MHC class Ia molecules [human lymphocyte antigen A (HLA-A), HLA-B, and HLA-C in humans and H-2K, H-2D, and H-2L in mice]. Here we show that CTLs recognized peptides presented by nonclassical MHC class Ib molecule Qa-1b expressed by tumor cells. These CTLs conferred in vivo protection by delaying the growth of Qa-1b-expressing B78H1 melanoma cells pulsed with Qa-1b-binding peptides Cw4L or B35L and injected s.c. in C57BL/6 mice. A hierarchy of the peptides was found with regard to their ability to trigger CTLs; Cw4L stimulated a strong CTL response. The closely related and cross-reactive peptide B35L induced a weaker CTL response but was still efficient in sensitizing the target cells. Finally, Qa-1b-expressing melanoma cells without exogenous peptides were not immunogenic but possibly expressed endogenous cross-reactive antigenic peptides. The data are compatible with earlier findings that CTL activation requires relatively strong peptide antigens, whereas subsequent effector functions are also mediated by weak peptide analogues. In conclusion, CTLs mediated tumor immunity through the recognition of peptides presented by nonclassical MHC class Ib molecules. The identification of similar CTLs in humans may facilitate the vaccination of cancer patients because MHC class Ib/peptide complexes are much less polymorphic than MHC class Ia/peptide complexes.

AB - Cytotoxic T Cells (CTLs) can exhibit considerable antitumor activity. Thus far, the characterized tumor peptide antigens recognized by CTLs are all presented by classical MHC class Ia molecules [human lymphocyte antigen A (HLA-A), HLA-B, and HLA-C in humans and H-2K, H-2D, and H-2L in mice]. Here we show that CTLs recognized peptides presented by nonclassical MHC class Ib molecule Qa-1b expressed by tumor cells. These CTLs conferred in vivo protection by delaying the growth of Qa-1b-expressing B78H1 melanoma cells pulsed with Qa-1b-binding peptides Cw4L or B35L and injected s.c. in C57BL/6 mice. A hierarchy of the peptides was found with regard to their ability to trigger CTLs; Cw4L stimulated a strong CTL response. The closely related and cross-reactive peptide B35L induced a weaker CTL response but was still efficient in sensitizing the target cells. Finally, Qa-1b-expressing melanoma cells without exogenous peptides were not immunogenic but possibly expressed endogenous cross-reactive antigenic peptides. The data are compatible with earlier findings that CTL activation requires relatively strong peptide antigens, whereas subsequent effector functions are also mediated by weak peptide analogues. In conclusion, CTLs mediated tumor immunity through the recognition of peptides presented by nonclassical MHC class Ib molecules. The identification of similar CTLs in humans may facilitate the vaccination of cancer patients because MHC class Ib/peptide complexes are much less polymorphic than MHC class Ia/peptide complexes.

UR - http://www.scopus.com/inward/record.url?scp=0032532088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032532088&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 4682

EP - 4687

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 20

ER -